pyr
predomin
apelin
peptid
isoform
human
cardiovascular
system
plasma
date
studi
investig
pyr
metabol
vivo
rat
studi
examin
stabil
human
therefor
aim
develop
lcmsm
method
detect
quantif
intact
pyr
use
method
identifi
metabolit
gener
vivo
human
pyr
nmolmin
infus
six
healthi
human
volunt
minut
blood
collect
time
minut
infus
plasma
extract
presenc
guanidin
hydrochlorid
analys
lcmsm
report
highli
sensit
robust
reproduc
method
quantif
intact
pyr
metabolit
human
plasma
use
method
show
circul
concentr
intact
peptid
ngml
minut
infus
demonstr
first
time
human
pyr
cleav
termini
ctermin
suscept
cleavag
consequ
metabolit
identifi
pyr
pyr
pyr
abund
data
suggest
apelin
peptid
design
use
cardiovascular
therapeut
includ
modif
minimis
ctermin
cleavag
apelin
endogen
ligand
apelin
receptor
initi
characteris
bovin
stomach
extract
acid
preproprotein
preproapelin
cleav
shorter
function
fragment
includ
pyr
contain
evolutionari
conserv
acid
ctermin
pyr
subsequ
identifi
predomin
isoform
apelin
famili
peptid
cardiovascular
system
major
circul
form
peptid
cardiovascular
system
apelin
potent
endogen
inotrop
agent
yet
identifi
apelin
modul
vascular
tone
vivo
decreas
blood
pressur
infus
rat
dilat
resist
vessel
infus
human
forearm
vitro
apelin
caus
nitric
oxidedepend
vasodil
human
splanchnic
arteri
although
nitric
oxideindepend
prostanoid
depend
vasodil
human
report
apelin
act
vasoconstrictor
endothelium
denud
vessel
via
direct
action
vascular
smooth
muscl
cell
whilst
also
act
potent
angiogen
factor
mitogen
endotheli
cell
base
benefici
effect
apelin
propos
potenti
therapeut
target
cardiovascular
diseas
exampl
apelin
administr
show
cardioprotect
effect
heart
failur
amelior
develop
pulmonari
arteri
hypertens
rat
human
addit
protect
effect
apelin
report
metabol
diseas
decreas
adipos
serum
insulin
increas
insulin
sensit
renal
diseas
decreas
acut
renal
injuri
fibrosi
recent
emerg
apelin
protumorigen
effect
variou
cancer
model
possibl
promot
angiogenesi
inhibit
apelin
pathway
protect
tumour
growth
howev
benefici
effect
apelin
peptid
limit
rapid
vivo
metabol
previou
studi
investig
metabol
apelin
peptid
larg
conduct
plasma
vitro
rodent
model
neither
may
repres
metabol
human
studi
demonstr
apelin
peptid
labil
plasma
halflif
less
minut
vitro
plasma
instabl
date
attribut
enzymat
activ
neprilysin
angiotensin
convert
enzym
ii
recent
plasma
kallikrein
similarli
anoth
recent
studi
report
rapid
degrad
pyr
rat
mous
plasma
compar
dog
monkey
human
plasma
vitro
author
also
confirm
find
vivo
rat
mous
identifi
ntermin
metabolit
peptid
particularli
abund
studi
therefor
highlight
speci
differ
repertoir
proteas
circul
present
rodent
higher
mammalian
system
howev
date
studi
investig
metabol
apelin
peptid
vivo
human
aim
studi
develop
highli
sensit
mass
spectrometri
base
method
detect
quantif
apelin
peptid
plasma
use
method
measur
intact
pyr
metabolit
gener
human
follow
constant
minut
infus
peptid
found
pyr
cleav
smaller
fragment
termini
ctermin
suscept
identifi
biolog
activ
ctermin
cleavag
product
pyr
abund
well
identifi
novel
metabolit
includ
pyr
pyr
precis
accuraci
extract
quantif
method
calibr
line
gener
pyr
human
plasma
r
data
shown
lower
limit
quantif
lloq
ngml
rel
error
calibr
standard
less
lloq
level
conform
typic
bioanalyt
method
valid
guidelin
precis
accuraci
qc
sampl
show
method
robust
accur
lloq
sampl
return
coeffici
variat
cv
whilst
qc
level
cv
repres
chromatogram
obtain
calibr
standard
shown
fig
obtain
infus
pyr
chromatograph
peak
observ
peptid
fig
b
sampl
obtain
end
infus
minut
show
strong
peak
minut
correspond
pyr
fig
measur
concentr
pyr
sampl
minut
ngml
addit
data
six
donor
control
sampl
receiv
pyr
apelin
infus
show
endogen
level
pyr
apelin
sampl
lloq
see
supplementari
fig
peak
height
obtain
chromatogram
donor
sampl
maximum
height
seen
lloq
consid
blank
quantit
purpos
base
fda
method
valid
guidelin
demonstr
select
lcm
methodolog
identif
potenti
ctermin
metabolit
pyr
order
identifi
potenti
metabolit
pyr
gener
minut
infus
period
sampl
reanalys
use
high
resolut
mass
spectromet
full
scan
lcm
data
interrog
potenti
pyr
deriv
metabolit
compar
extract
ion
chromatogram
analyt
minut
sampl
qualbrows
softwar
packag
thermofish
peptid
identifi
minut
sampl
mainli
gener
loss
ctermin
amino
acid
fig
rel
abund
sampl
display
fig
notabl
abund
fragment
pyr
known
biolog
activ
pyr
pyr
metabolit
identifi
although
lower
level
parent
pyr
includ
pyr
pyr
pyr
like
biolog
inact
chromatograph
spectra
correspond
metabolit
shown
fig
g
addit
pyr
abund
metabolit
identifi
pyr
fig
pyr
fig
present
suffici
level
gener
suitabl
product
ion
spectra
allow
experiment
acquir
fragment
match
theoret
fragment
peptid
sequenc
rel
mass
accuraci
potenti
metabolit
gener
experiment
valu
within
ppm
expect
valu
whilst
mass
accuraci
parent
peptid
highest
valu
ppm
oxid
methionin
residu
pyr
identifi
howev
sinc
modif
also
observ
extract
standard
could
ascertain
occur
vivo
artefact
extract
process
identif
potenti
ntermin
metabolit
pyr
use
approach
describ
sever
ntermin
metabolit
pyr
identifi
fig
note
peak
area
fragment
lower
compar
observ
ctermin
fragment
abund
ntermin
fragment
observ
pyr
pyr
pyr
pyr
fig
b
fragment
present
low
abund
includ
pyr
pyr
pyr
mass
accuraci
experiment
acquir
monoisotop
mz
metabolit
shown
fig
within
ppm
expect
valu
develop
valid
high
resolut
lcmsm
method
detect
quantif
pyr
rel
quantif
metabolit
vivo
human
plasma
shown
method
robust
reproduc
high
sensit
pyr
lloq
ngml
use
method
quantifi
intact
peptid
constant
infus
minut
healthi
volunt
show
first
time
human
vivo
pyr
cleav
nand
ctermini
cterminu
suscept
proteolyt
activ
abund
metabolit
identifi
method
pyr
high
level
pyr
pyr
also
detect
sequenc
confirm
use
tandem
mass
spectrometri
manual
product
ion
match
discoveri
pyr
cleav
end
unexpect
sinc
date
cleavag
cterminu
describ
find
may
therefor
better
explain
extrem
unstabl
natur
apelin
peptid
plasma
worth
note
cterminu
suscept
proteolyt
activ
nterminu
whose
metabolit
present
approxim
lower
level
may
partli
explain
pyroglutamyl
nterminu
may
protect
region
enzymat
activ
degre
nterminu
pyr
also
contain
rprl
motif
critic
bind
apelin
receptor
henc
cleavag
direct
like
profoundli
affect
affin
ntermin
fragment
receptor
previou
studi
show
vitro
neprilysin
cleav
pyr
arg
leu
leu
ser
amino
acid
therebi
make
neprilysin
first
enzym
identifi
date
complet
inactiv
peptid
importantli
shown
studi
presenc
one
propos
neprilysin
cleavag
product
human
vivo
minut
retent
time
data
acquir
use
orbitrap
mass
spectromet
use
metabolit
identif
mass
accuraci
experiment
acquir
monoisotop
peak
calcul
potenti
metabolit
includ
along
c
isotop
cluster
peptid
correspond
chromatogram
wwwnaturecomscientificreport
wwwnaturecomscientificreport
addit
evid
cleavag
scissil
bond
leu
ser
given
detect
ctermin
fragment
pyr
date
studi
investig
metabol
peptid
vivo
human
interestingli
like
pyr
arginin
vasopressin
also
propos
cleav
vivo
cand
ntermini
carboxypeptidas
postprolin
enzym
cleav
cterminu
arginin
vasopressin
aminopeptidas
cleav
ntermin
region
contrast
vivo
studi
natur
identifi
singl
terminu
cleavag
peptid
yy
growth
hormonereleas
hormon
liraglutid
glucagonlik
analogu
big
previou
vitro
studi
plasma
suggest
pyr
metabolit
pyr
produc
enzymat
activ
result
remov
ctermin
phenylalanin
howev
unclear
whether
metabolit
retain
biolog
activ
apelin
receptor
one
studi
argu
pyr
reduc
biolog
activ
compar
nativ
pyr
measur
hypotens
effect
mice
howev
yang
et
al
demonstr
metabolit
pyr
contract
human
saphen
vein
subnanomolar
potenc
potent
posit
inotrop
pace
mous
human
heart
ex
vivo
author
demonstr
pyr
present
endogen
endothelium
human
heart
lung
went
show
biolog
activ
vivo
human
rodent
similarli
previou
studi
report
pyr
cleav
pyr
vivo
rat
consist
studi
work
provid
clear
evid
pyr
produc
endogen
human
plasma
vivo
possibl
via
activ
pyr
also
cleav
pro
met
ser
result
gener
pyr
pyr
enzym
respons
produc
metabolit
remain
unknown
correspond
ntermin
fragment
ctermin
metabolit
pyr
wwwnaturecomscientificreport
wwwnaturecomscientificreport
pyr
also
identifi
data
consist
previou
vivo
studi
male
rat
also
identifi
ctermin
metabolit
author
report
accumul
pyr
pyr
metabolit
pyr
pyr
retain
rprl
motif
requir
bind
although
unclear
retain
biolog
activ
taken
togeth
find
may
suggest
least
common
metabol
pathway
pyr
rat
human
vivo
studi
requir
identifi
specif
proteas
involv
inhibit
degrad
enzym
wellestablish
strategi
gener
therapeut
agent
import
member
reninangiotensin
system
convert
angiotensinii
angiotensin
latter
mediat
vasodilat
antiprolifer
antiapoptosi
antifibrot
effect
addit
implic
heart
failur
diabet
nephropathi
acut
lung
failur
lung
injuri
induc
lethal
avian
influenza
viru
respiratori
syncyti
viru
sever
acut
respiratori
syndrom
sar
recent
gsk
develop
recombin
human
treatment
acut
respiratori
distress
syndrom
ard
show
molecul
welltoler
clinic
trial
corrobor
apelin
signal
induc
express
fail
heart
protect
lung
injuri
experiment
model
acut
respiratori
distress
syndrom
possibl
inhibit
pathway
compon
inflammasom
furthermor
apelin
counteract
effect
angiotensinii
signal
neg
regul
suggest
target
apelin
could
potenti
novel
therapeut
strategi
treatment
lung
injuri
relat
patholog
heart
failur
benefici
effect
apelin
heart
failur
well
characteris
plasma
apelin
level
suggest
increas
earli
stage
heart
failur
decreas
late
stage
diseas
support
heart
failur
therapi
cardiac
resynchronis
therapi
use
treat
refractori
chronic
heart
failur
shown
increas
plasma
apelin
suggest
increas
apelin
level
associ
improv
therapeut
benefit
apelin
administr
increas
stroke
volum
contractil
fail
heart
therebi
improv
perform
fail
heart
similarli
neprilysin
inhibitor
emerg
pivot
therapeut
strategi
clinic
manag
heart
failur
due
role
neprilysin
degrad
vasoact
peptid
includ
natriuret
peptid
bradykinin
inde
neprilysin
inhibitor
sacubitril
use
clinic
manag
heart
failur
data
may
therefor
suggest
addit
benefit
neprilysin
inhibitor
heart
failur
reduc
apelin
inactiv
result
benefici
vasodil
increas
contractil
cardiac
output
build
find
studi
could
substitut
amino
acid
neprilysin
cleavag
site
pyr
unnatur
amino
acid
improv
resist
degrad
inde
recent
shown
infus
neprilysin
resist
establish
mice
model
abdomin
aortic
aneurysm
amelior
advers
aortic
remodel
aneurysm
format
strategi
also
demonstr
significantli
increas
resist
pyr
activ
suggest
could
potenti
mechan
improv
plasma
stabil
apelinbas
therapeut
clinic
indic
recent
publish
anoth
approach
stabilis
apelin
peptid
human
blood
use
albumin
domain
albudab
antibodi
conjug
apelin
analogu
show
peptid
resist
degrad
yet
retain
biolog
activ
human
apelin
receptor
vitro
vivo
therefor
strategi
could
near
futur
result
develop
first
apelinbas
therapeut
treatment
human
diseas
wwwnaturecomscientificreport
wwwnaturecomscientificreport
conclus
apelin
peptid
protect
role
cardiovascular
diseas
howev
potenti
therapeut
use
impair
poor
plasma
stabil
peptid
studi
develop
highli
sensit
method
detect
quantif
human
plasma
first
time
human
vivo
identifi
abund
metabolit
pyr
cleavag
product
pyr
previous
demonstr
retain
signific
biolog
activ
addit
put
neprilysin
metabolit
pyr
pyr
combin
inhibit
neprilysin
may
novel
strategi
enhanc
endogen
apelin
level
condit
peptid
downregul
addit
data
inform
design
stabl
apelin
peptid
therapeut
use
materi
retent
time
minut
c
pyr
retent
time
minut
pyr
retent
time
minut
e
pyr
retent
time
minut
mass
accuraci
experiment
acquir
monoisotop
peak
calcul
potenti
metabolit
includ
along
c
isotop
cluster
peptid
correspond
chromatogram
wwwnaturecomscientificreport
wwwnaturecomscientificreport
healthi
volunt
male
femal
mean
age
bodi
mass
index
within
normal
rang
recruit
infus
volunt
fast
lie
supin
head
support
quiet
temperatur
control
room
durat
studi
follow
period
acclimatis
first
sampl
venou
blood
obtain
arm
contralater
arm
use
infus
apelin
vial
contain
pyr
allow
warm
room
temperatur
dilut
physiolog
salin
produc
stock
solut
filter
use
portex
flat
filter
portex
uk
undergo
serial
dilut
steril
salin
loss
apelin
follow
filtrat
procedur
volunt
infus
concentr
nmolmin
pyr
rate
mlmin
minut
use
syring
pump
equip
ml
syring
gaug
cathet
second
venou
sampl
obtain
immedi
end
infus
blood
sampl
collect
ml
edta
tube
immedi
put
wet
ice
centrifug
minut
rpm
store
prior
analysi
previou
studi
use
concentr
nmolmin
system
infus
obtain
therapeut
respons
patient
pulmonari
arteri
hypertens
highest
dose
well
toler
dose
chosen
nmolmin
pyr
slightli
higher
order
identifi
possibl
metabolit
addit
control
sampl
obtain
donor
male
femal
within
similar
age
group
receiv
apelin
infus
comparison
full
scan
analysi
peptid
show
h
charg
state
predomin
ion
spectrum
previous
describ
mesmin
et
al
lcmsm
analysi
pyr
therefor
select
fragment
product
ion
spectrum
collect
rang
mz
two
ion
select
srm
optimis
mz
ion
correspond
fragment
ion
deriv
loss
methylsulphid
group
methionin
ion
previous
describ
mesmin
et
al
peptid
peak
area
integr
use
targetlynx
program
associ
masslynx
v
water
peak
area
ratio
gener
correspond
stabl
isotopelabel
intern
standard
peptid
peak
extract
pyr
human
plasma
plasma
sampl
thaw
ice
transfer
protein
lobind
eppendorf
tube
contain
guhcl
aliquot
acn
water
contain
ngml
intern
standard
ad
plasma
sampl
vortex
centrifug
x
g
minut
precipit
plasma
protein
supernat
transfer
ml
protein
lobind
plate
evapor
sampl
reconstitut
fa
vv
load
onto
oasi
hlb
prime
plate
water
wilmslow
uk
slowli
extract
posit
pressur
manifold
water
column
wash
methanol
water
acet
acid
vv
elut
cartridg
use
methanol
water
acet
acid
vv
eluat
evapor
dryness
reconstitut
fa
vv
water
inject
onto
lcmsm
system
precis
accuraci
extract
method
blank
plasma
preincub
least
hour
degrad
endogen
pyr
use
gener
eight
point
calibr
line
custom
synthesis
pyr
rang
ngml
aliquot
calibr
standard
ngml
extract
use
spe
method
describ
four
level
qc
also
gener
ngml
extract
six
time
order
assess
precis
accuraci
method
calibr
line
follow
linear
fit
weight
appli
recoveri
pyr
plasma
assess
analys
spike
solut
extract
concentr
ngml
plasma
sampl
six
individu
also
extract
assess
select
lcmsm
method
peptid
identif
use
highresolut
mass
spectrometri
sampl
reanalys
high
resolut
mass
spectromet
identifi
potenti
metabolit
administ
pyr
peptid
full
scan
analysi
perform
use
thermoscientif
ultim
lc
system
connect
thermoscientif
orbitrap
qexact
plu
mass
spectromet
solvent
use
separ
fa
water
vv
b
fa
acn
vv
volum
extract
inject
onto
hss
uplc
column
mm
water
elstre
uk
held
flow
rate
start
condit
b
use
captur
hydrophil
peptid
metabolit
elut
use
linear
gradient
b
minut
column
wash
minut
b
return
start
condit
minut
total
run
time
minut
mass
spectrometri
perform
use
posit
electrospray
mode
needl
voltag
kv
ga
set
sheath
ga
aux
ga
flow
rate
temperatur
ga
set
transfer
capillari
slen
valu
v
full
scan
data
acquir
mz
rang
use
resolut
maximum
fill
time
wwwnaturecomscientificreport
wwwnaturecomscientificreport
ms
acquir
lcm
data
interrog
potenti
pyr
metabolit
search
potenti
cleavag
product
parent
peptid
raw
data
file
use
qualbrows
softwar
packag
thermofish
mz
valu
peptid
multipl
charg
state
display
supplementari
tabl
potenti
pyr
metabolit
manual
identifi
subsequ
characteris
sampl
reinject
use
target
msm
analysi
potenti
pyr
pyr
peptid
target
use
precursor
ion
mz
valu
collis
energi
collis
energi
respect
msm
analysi
involv
lc
separ
ms
ms
data
acquir
resolut
agc
ion
lowest
mz
valu
max
fill
time
ms
data
gener
analys
studi
includ
publish
articl
